Login to Your Account



Another $275M in Potential Milestones

Astrazeneca’s Gambit: $225M for Early Stage Amplimmune

By Randy Osborne
Staff Writer

Wednesday, August 28, 2013
Astrazeneca plc’s buyout of Amplimmune Inc. for $225 million up front could put the pipeline-strapped pharma giant high on the short list of leaders in combination immunotherapy, if the latter’s early stage candidates pan out, and the deal carries another $275 million in potential milestone payments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription